Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of the CGRP Binding Monoclonal Antibody LY2951742 (Galcanezumab) in Healthy Volunteers

Safety and efficacy of AMG 334 for prevention of episodic migraine: a randomised, double-blind, placebo-controlled, phase 2 trial

(2016) Hong Sun et al.   LANCET NEUROLOGY

Wiping Out CGRP: Potential Cardiovascular Risks

(2016) Antoinette MaassenVanDenBrink et al.   TRENDS IN PHARMACOLOGICAL SCIENCES

Development of anti-migraine therapeutics using the capsaicin-induced dermal blood flow model

(2015) Linde Buntinx et al.   BRITISH JOURNAL OF CLINICAL PHARMACOLOGY

Calcitonin gene-related peptide and migraine

(2015) Nazia Karsan et al.   CURRENT OPINION IN NEUROLOGY

Safety, tolerability, and efficacy of TEV-48125 for preventive treatment of chronic migraine: a multicentre, randomised, double-blind, placebo-controlled, phase 2b study

(2015) Marcelo E Bigal et al.   LANCET NEUROLOGY

Safety, tolerability, and efficacy of TEV-48125 for preventive treatment of high-frequency episodic migraine: a multicentre, randomised, double-blind, placebo-controlled, phase 2b study

(2015) Marcelo E Bigal et al.   LANCET NEUROLOGY

Safety and efficacy of LY2951742, a monoclonal antibody to calcitonin gene-related peptide, for the prevention of migraine: a phase 2, randomised, double-blind, placebo-controlled study

(2014) David W Dodick et al.   LANCET NEUROLOGY

Safety and efficacy of ALD403, an antibody to calcitonin gene-related peptide, for the prevention of frequent episodic migraine: a randomised, double-blind, placebo-controlled, exploratory phase 2 trial

(2014) David W Dodick et al.   LANCET NEUROLOGY

Randomized controlled trial of the CGRP receptor antagonist telcagepant for migraine prevention

(2014) T. W. Ho et al.   NEUROLOGY

Lack of hemodynamic interaction between CGRP-receptor antagonist telcagepant (MK-0974) and sumatriptan: Results from a randomized study in patients with migraine

(2013) M Depré et al.   CEPHALALGIA

Pearls and pitfalls in neural CGRP immunohistochemistry

(2013) Karin Warfvinge et al.   CEPHALALGIA

Calcitonin gene-related peptide (CGRP) and its receptor components in human and rat spinal trigeminal nucleus and spinal cord at C1-level

(2012) Sajedeh Eftekhari et al.   BMC NEUROSCIENCE

Disability-adjusted life years (DALYs) for 291 diseases and injuries in 21 regions, 1990–2010: a systematic analysis for the Global Burden of Disease Study 2010

(2012) Christopher J L Murray et al.   LANCET

Chronic migraine—classification, characteristics and treatment

(2012) Hans-Christoph Diener et al.   Nature Reviews Neurology

Chronic Migraine, Classification, Differential Diagnosis, and Epidemiology

(2011) Richard B. Lipton   HEADACHE

Antidromic vasodilatation and the migraine mechanism

(2011) Pierangelo Geppetti et al.   JOURNAL OF HEADACHE AND PAIN

Evidence for a vascular factor in migraine

(2010) Mohammad S. Asghar et al.   ANNALS OF NEUROLOGY

The potent calcitonin gene-related peptide receptor antagonist, telcagepant, does not affect nitroglycerin-induced vasodilation in healthy men

(2010) Bart J. Van der Schueren et al.   BRITISH JOURNAL OF CLINICAL PHARMACOLOGY

Calcitonin gene-related peptide triggers migraine-like attacks in patients with migraine with aura

(2010) Jakob Møller Hansen et al.   CEPHALALGIA

Calcitonin Gene-Related Peptide (CGRP) Receptor Antagonists in the Treatment of Migraine

(2010) Paul L. Durham et al.   CNS DRUGS

CGRP and its receptors provide new insights into migraine pathophysiology

(2010) Tony W. Ho et al.   Nature Reviews Neurology

Inhibition of capsaicin-induced increase in dermal blood flow by the oral CGRP receptor antagonist, telcagepant (MK-0974)

(2009) Simon R. Sinclair et al.   BRITISH JOURNAL OF CLINICAL PHARMACOLOGY

CGRP function-blocking antibodies inhibit neurogenic vasodilatation without affecting heart rate or arterial blood pressure in the rat

(2008) J Zeller et al.   BRITISH JOURNAL OF PHARMACOLOGY

Calcitonin receptor-like receptor (CLR), receptor activity-modifying protein 1 (RAMP1), and calcitonin gene-related peptide (CGRP) immunoreactivity in the rat trigeminovascular system: Differences between peripheral and central CGRP receptor distribution

(2008) Jochen K. Lennerz et al.   JOURNAL OF COMPARATIVE NEUROLOGY

Calcitonin Gene-Related Peptide8-37 Antagonizes Capsaicin-Induced Vasodilation in the Skin: Evaluation of a Human in Vivo Pharmacodynamic Model

(2008) B. J. Van der Schueren et al.   JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS

Efficacy and tolerability of MK-0974 (telcagepant), a new oral antagonist of calcitonin gene-related peptide receptor, compared with zolmitriptan for acute migraine: a randomised, placebo-controlled, parallel-treatment trial

(2008) Tony W Ho et al.   LANCET